Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Enalapril Maleate: adverse event reports

All products with this active ingredient · 1 FDA-approved application in the Green Book

2,056reports naming this ingredient, 1994–20260.2% of all reports · about 65 a year
143reports, 12 months to March 2026162 in the 12 months before
50.5%classed serious, as reportedof 1,541 reports stating it
14.2%record death or euthanasia, as reported292 reports
79.1%of reports concern dogs0.2% of all dog reports

2,056 adverse event reports in FDA's database list a drug whose active ingredient is recorded as enalapril maleate. The earliest was received in June 1994, the latest in March 2026. The Green Book lists 1 FDA-approved application with this single active ingredient.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 143 reports named it, down 12% from 162 in the 12 months before. Recent months are provisional: fDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 65 reports a year and 0.2% of all 1,357,245 reports (0.2% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The most frequently coded terms are lethargy (13.9%), vomiting (12.5%) and diarrhoea (10.5%). A report can list several signs, so shares add to more than 100%; 973 different terms appear across these reports.

79.1% of reports concern dogs. Not every report describes illness: 16.7% as product or packaging defects. Of reports that state seriousness, 50.5% were classed as serious, and 14.2% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog534 · peak 19
Apr 2021: 6May 2021: 8Jun 2021: 7Jul 2021: 15Aug 2021: 6Sep 2021: 3Oct 2021: 8Nov 2021: 6Dec 2021: 3Jan 2022: 5Feb 2022: 11Mar 2022: 8Apr 2022: 11May 2022: 10Jun 2022: 5Jul 2022: 7Aug 2022: 14Sep 2022: 7Oct 2022: 9Nov 2022: 6Dec 2022: 7Jan 2023: 2Feb 2023: 8Mar 2023: 5Apr 2023: 5May 2023: 14Jun 2023: 6Jul 2023: 3Aug 2023: 3Sep 2023: 5Oct 2023: 8Nov 2023: 8Dec 2023: 10Jan 2024: 12Feb 2024: 13Mar 2024: 16Apr 2024: 12May 2024: 13Jun 2024: 18Jul 2024: 10Aug 2024: 17Sep 2024: 19Oct 2024: 13Nov 2024: 10Dec 2024: 14Jan 2025: 10Feb 2025: 7Mar 2025: 7Apr 2025: 12May 2025: 15Jun 2025: 9Jul 2025: 3Aug 2025: 11Sep 2025: 6Oct 2025: 5Nov 2025: 12Dec 2025: 6Jan 2026: 10Feb 2026: 10Mar 2026: 52022202320242025
Cat61 · peak 8
Feb 2023: 1Mar 2023: 2May 2023: 1Aug 2023: 2Nov 2023: 1Dec 2023: 1Jan 2024: 1Mar 2024: 1Apr 2024: 3May 2024: 1Jun 2024: 2Oct 2024: 1Dec 2024: 1Jan 2025: 1Feb 2025: 1Mar 2025: 2Apr 2025: 6May 2025: 1Jun 2025: 1Jul 2025: 2Aug 2025: 2Sep 2025: 4Oct 2025: 5Nov 2025: 6Dec 2025: 8Jan 2026: 3Feb 2026: 12022202320242025
Horse0 · peak 1
2022202320242025
Other1 · peak 1
Oct 2023: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

0891771994: 519941995: 41996: 21997: 119971998: 11999: 92000: 920002001: 82002: 82003: 2820032004: 742005: 452006: 3520062007: 472008: 512009: 3820092010: 402011: 902012: 14420122013: 1482014: 862015: 7920152016: 1162017: 1072018: 11520182019: 772020: 752021: 8020212022: 1002023: 862024: 17720242025: 1422026: 29

2026 covers reports received through March 2026 only.

Signs listed in reports

share of enalapril maleate reports listing the termall dog reports

  1. Lethargy[unusually tired or inactive]13.9%286
  2. Vomiting12.5%257
  3. Diarrhoea[diarrhea]10.5%215
  4. Death by euthanasia[the animal was euthanized]8.5%174
  5. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]6.7%137
  6. Anorexia[not eating]6.6%135
  7. Containers, Damaged[a product quality report, not a sign in an animal]6.5%133
  8. Seizure NOS[seizure, type not specified]6%124
  9. Death5.6%115
  10. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]4.8%98
  11. Elevated creatinine[a kidney value above the normal range]4.5%92
  12. Ataxia[unsteady, uncoordinated movement]4.3%89
  13. Emesis[vomiting]4.2%87
  14. Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]4.2%86
  15. Lack of efficacy - NOS[the product did not have the expected effect]4.1%84
  16. Cough3.7%76
  17. Other abnormal test result NOS[abnormal laboratory result, type not specified]3.6%74
  18. Hyperkalaemia[high blood potassium]3.5%72
  19. Polydipsia[drinking more than usual]3.3%67
  20. Behavioural disorder NOS[behaviour change, type not specified]3.2%66
  21. Underfilling, Package[a product quality report, not a sign in an animal]3%62
  22. Polyuria[passing more urine than usual]2.9%59
  23. Panting2.8%58
  24. Hyperphosphataemia[high blood phosphate]2.7%56
  25. Depression[dull, quiet or withdrawn]2.3%47
  26. Anaemia NOS[low red blood cell count]2.1%43

Top 30 of 973 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal19.6%403
Recovered with Sequela1.8%37
Ongoing19.2%394
Died6.4%132
Euthanized7.9%162
Outcome Unknown23%472

What kind of report it was

Safety issue75%1,541
Lack of expected effectiveness3.8%79
Both safety and lack of expected effectiveness4.4%90
Manufacturing or product defect16.7%344
Other0.1%2

Coloured bar: reports naming enalapril maleate. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog79.1%1,626
Cat5%103
Human exposure0.3%6
Other Birds0%1

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year0.2%4
1 to 3 years1.7%34
4 to 7 years5.6%115
8 to 11 years29.1%598
12 years and over45.1%927
Age not given18.4%378

Weight of the animal

Under 5 kg (11 lb)20.7%425
5 to 9.9 kg (11–22 lb)30.4%625
10 to 24.9 kg (22–55 lb)19%391
25 to 44.9 kg (55–99 lb)9.1%188
45 kg and over (99 lb+)1.5%31
Weight not given19.3%396

Route of administration stated in reports: oral (1,099), ophthalmic (1), other (1), transdermal (1), vaginal (1).

In context

MeasureEnalapril MaleateAll dog reportsAll reports
Reports2,056985,6751,357,245
Share of that pool's reports naming this drug—0.2%0.2%
Classed serious, of reports stating it50.5%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports1425563.8
Filed as lack of expected effectiveness (wholly or partly)8.2%—23%
Top term, share of reportsLethargy 13.9%7.9%—

This set accounts for 100% of all reports naming enalapril maleate, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products containing enalapril maleate (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 30 Sep 2026; nothing on this page says which of these products, if any, a report concerned.

Only one approved application matches this ingredient set. FDA's records still do not say which product a report concerned: the same ingredients are also dispensed as compounded, foreign-labelled and unapproved products, and the ingredient field is completed by whoever submitted the report.

Trade nameActive ingredientsSponsorApproved forApplication
Enacard Tablets For Dogsapproval voluntarily withdrawnEnalapril MaleateBoehringer Ingelheim Animal Health USA Inc.DogsNADA 141-015

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about enalapril maleate reports

How many adverse event reports has FDA received for enalapril maleate?

2,056 reports record a drug with enalapril maleate as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 143 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 1 approved application with this ingredient alone; the reference list on this page names them without any counts.

What signs are reported most often?

lethargy (13.9%), vomiting (12.5%), diarrhoea (10.5%), death by euthanasia (8.5%) and elevated blood urea nitrogen (BUN) (6.7%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (79.1%), cat (5%) and human exposure (0.3%). Among single-breed animals the most frequent labels are Chihuahua, Yorkshire Terrier, Shih Tzu and Cavalier King Charles Spaniel; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

143 reports in the 12 months to March 2026, down 12% from 162 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that enalapril maleate harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of enalapril maleate?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 30 Sep 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.